Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/8/2019
SIETES contiene 92794 citas

 
 
 1 a 20 de 50 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Fanning L, Ilomäki J, Bell JS, Darzinš P. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. Eur J Clin Pharmacol 2017;73:1427-36. [Ref.ID 102129]
2.Enlace a cita original Cita con resumen
Mahtani KR, Heneghan C. Novel oral anticoagulants for atrial fibrillation. BMJ 2016;354:i5187. [Ref.ID 100782]
3. Cita con resumen
Anónimo. Which oral anticoagulant for atrial fibrillation?. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:45-6. [Ref.ID 100209]
4.Tiene citas relacionadas Cita con resumen
Christopoulos C. Questions about the reliability of ROCKET-AF anticoagulation data. BMJ 2016;352:i1039. [Ref.ID 100063]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Marciniak TA, Cherepanov V, Golukhova I, Hyun Kim M, Serebruany V. Drug discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern Med 2016;176:11 de enero. [Ref.ID 99961]
6. Cita con resumen
Anónimo. Drug problems: dangerous decision-making at the FDA. POGO. Project on Government Oversight 2015:15 de octubre. [Ref.ID 99569]
7.Tiene citas relacionadas Cita con resumen
Sarrazin MSV, Rose A. Safety of new oral anticoagulants. BMJ 2015;350:h1679. [Ref.ID 98980]
8.Tiene citas relacionadas Cita con resumen
Chang H-Y, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350:h1585. [Ref.ID 98979]
9.Tiene citas relacionadas Cita con resumen
Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857. [Ref.ID 98978]
10. Cita con resumen
Hernández I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2014;175:18-24. [Ref.ID 98701]
11. Cita con resumen
Redberg RS. The importance of postapproval data for dabigatran. JAMA Intern Med 2015;175:25. [Ref.ID 98317]
12.Tiene citas relacionadas Cita con resumen
Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ 2014;349:g4517. [Ref.ID 98146]
13.Tiene citas relacionadas Cita con resumen
Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014;349:g4670. [Ref.ID 98145]
14. Cita con resumen
Husten L. Mixed results on Pradaxa from FDA. Journal Watch 2014:14 de mayo. [Ref.ID 97519]
16. Cita con resumen
Ruff ChT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62. [Ref.ID 97286]
17. Cita con resumen
Xu Y, Holbrook AM, Simpson CS, Dowlatshahi D, Johnson AP. Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. Can Med Assoc J 2013;1:E115-119. [Ref.ID 96246]
18. Cita con resumen
Majeed A, Hwang H-G, Connolly SJ, Elkelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013;128:2325-32. [Ref.ID 96223]
19.Enlace a cita original Cita con resumen
Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensy G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation 2013;128:237-43. [Ref.ID 95955]
20. Cita con resumen
Bosch M, Llop R, Lalueza P, Villar MM. Nuevos anticoagulantes orales para la prevención del ictus en pacientes con fibrilación auricular no valvular. Med Clin (Barc) 2013;140:229-31. [Ref.ID 95047]
Seleccionar todas
 
 1 a 20 de 50 siguiente >>